Home › Research › Treatments
Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease
Curd BC, Tolley ND, Santo M, Foster J, Leardini-Tristão M, Jacob S, Benzon H, Ye X et al.. Journal of thrombosis and thrombolysis, 2026-08-20
Topic: Amyloid, tau and blood-test diagnosis
Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer's disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H). Whether anti-amyloid therapy is associated with systemic alterations in coagulation function is unknown. We sought to evaluate systemic coagulation function in patients receiving lecanemab compared with untreated AD controls. We prospectively collected blood samples from 20 lecanemab-treated participants with AD at baseline and after 8-10 weeks of therapy, and from 48 untreated AD controls. We assessed thrombin generation in platelet-poor plasma initiated with tissue factor and measured lag time, time to peak, peak thrombin, velocity, and area under the curve. We also evaluated fibrin formation by turbidity assays, yielding maximum rate of clot formation and time to Vmax. Comparisons were performed between groups and within treated participants over time. Mean age was 72.8 years (SD 8.1); 51.5% were female. No significant differences were observed in thrombin generation or fibrin formation between treated and untreated participants, or from baseline to follow-up among treated participants. Two lecanemab-treated participants developed ARIA-H. Anti-amyloid monoclonal antibody therapy was not associated with detectable alterations in plasma coagulation parameters in this cohort. These findings do not support measurable systemic coagulation perturbations detectable in plasma but do not rule out localized cerebrovascular, endothelial, platelet-mediated, or other microvascular mechanisms underlying ARIA-H, which warrant future investigation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Curd, B. C., Tolley, N. D., Santo, M., Foster, J., Leardini-Tristão, M., Jacob, S., et al. (2026). Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease. Journal of thrombosis and thrombolysis. https://doi.org/10.1007/s11239-026-03383-4
Vancouver
Curd BC, Tolley ND, Santo M, Foster J, Leardini-Tristão M, Jacob S, et al. Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease. Journal of thrombosis and thrombolysis. 2026. doi:10.1007/s11239-026-03383-4. PMID: 42622760.
BibTeX
@article{curd2026-42622760,
author = {Curd, B. C. and Tolley, N. D. and Santo, M. and Foster, J. and Leardini-Tristão, M. and Jacob, S. and Benzon, H. and Ye, X. and others},
title = {{Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease}},
journal = {Journal of thrombosis and thrombolysis},
year = {2026},
doi = {10.1007/s11239-026-03383-4},
pmid = {42622760},
url = {https://doi.org/10.1007/s11239-026-03383-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer's disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H).
- Whether anti-amyloid therapy is associated with systemic alterations in coagulation function is unknown.
- We sought to evaluate systemic coagulation function in patients receiving lecanemab compared with untreated AD controls.
- No significant differences were observed in thrombin generation or fibrin formation between treated and untreated participants, or from baseline to follow-up among treated participants.
- Anti-amyloid monoclonal antibody therapy was not associated with detectable alterations in plasma coagulation parameters in this cohort.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size51.5%
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 29 of the 58 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of thrombosis and thrombolysis) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42622760) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 29 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 29 of the 58 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “antibody-therapy”
3 studies in the library carry the topic tag “antibody-therapy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.